Related Experiment Videos
beta(2)-adrenoceptors activate nitric oxide synthase in human platelets
L R Queen1, B Xu, K Horinouchi
1Department of Clinical Pharmacology, Center for Cardiovascular Biology & Medicine, King's College London, St Thomas' Hospital, London, UK.
This study investigated whether beta(2)-adrenoceptors in human platelets can activate nitric oxide synthase (NOS), which produces nitric oxide (NO). The researchers found that stimulating beta(2)-adrenoceptors with isoproterenol or forskolin increased NOS activity in a cAMP-dependent manner. This activation was not associated with changes in intracellular calcium levels. The study also showed that isoproterenol inhibited platelet adhesion to endothelial cells, and this effect was blocked when NOS was inhibited. However, the anti-aggregatory effect of isoproterenol was not affected by NOS inhibition. The findings suggest that beta(2)-adrenoceptors may contribute to platelet adhesion inhibition via NO production but not to aggregation inhibition. The authors propose that the L-arginine/NO system mediates the effects of beta(2)-adrenoceptors on adhesion but not on aggregation.
Area of Science:
- Platelet biology within hematology
- Nitric oxide signaling in pharmacology
- Receptor-mediated signaling in cardiovascular research
Background:
Platelet function is crucial in hemostasis and thrombosis. Platelet adhesion and aggregation are tightly regulated by multiple signaling pathways. It is already known that nitric oxide (NO) limits platelet activation, and that beta-adrenoceptors (betaARs) inhibit aggregation. However, no direct connection has been established between betaAR stimulation and NO production in platelets. Prior research has shown that NO is synthesized via nitric oxide synthase (NOS) in platelets, but the role of betaARs in this process remains unclear. This gap motivated researchers to investigate whether betaARs could activate NOS in human platelets. The study aimed to clarify if betaAR stimulation influences NOS activity and whether this contributes to platelet inhibition. No prior work had resolved the mechanism linking betaARs and NOS in platelets. This uncertainty drove the current investigation into the relationship between betaARs and NO production in platelet function.
Purpose Of The Study:
The aim of this study was to determine if beta(2)-adrenoceptors (beta(2)ARs) in human platelets can activate nitric oxide synthase (NOS). The researchers sought to explore the mechanism by which betaAR stimulation might influence NO production and platelet behavior. They focused on whether betaAR activation leads to increased NOS activity and whether this activity affects platelet aggregation or adhesion. The study also aimed to identify which betaAR subtype is responsible for these effects. The motivation for this research stems from the lack of direct evidence linking betaARs to NOS activation in platelets. The researchers hypothesized that betaAR stimulation could increase NOS activity through a cAMP-dependent pathway. They also aimed to assess whether this NOS activation contributes to the anti-aggregatory or anti-adhesive effects of betaAR stimulation. The study sought to clarify the role of beta(2)ARs in modulating platelet function via NO production.
Main Methods:
The researchers measured nitric oxide synthase (NOS) activity in human platelets by tracking the conversion of L-[(3)H]-arginine to L-[(3)H]-citrulline. Platelet samples were obtained from human donors and treated with betaAR agonists or cAMP-elevating agents. Isoproterenol and forskolin were used to stimulate NOS activity, and their effects were compared to baseline measurements. The adenylyl cyclase inhibitor SQ225536 was used to determine if cAMP was involved in the observed NOS activation. Intracellular calcium levels were also monitored to assess whether NOS activation was calcium-dependent. Functional assays were conducted to evaluate the effect of isoproterenol on platelet aggregation and adhesion. Platelet aggregation was induced with U46619, and adhesion was tested using cultured human umbilical vein endothelial cells. BetaAR subtype-specific antagonists were used to confirm that the observed effects were mediated exclusively by beta(2)ARs. The study combined biochemical assays with functional platelet tests to evaluate the role of beta(2)ARs in NOS activation.
Main Results:
Isoproterenol and forskolin each increased NOS activity in human platelets, with isoproterenol raising activity from 0.11 to 0.26 pmol L-citrulline/10(8) platelets and forskolin from 0.11 to 0.23 pmol L-citrulline/10(8) platelets. The adenylyl cyclase inhibitor SQ225536 abolished this increase in NOS activity, indicating a cAMP-dependent mechanism. Neither isoproterenol nor forskolin altered intracellular calcium levels, suggesting that NOS activation was calcium-independent. Isoproterenol inhibited U46619-induced platelet aggregation in a concentration-dependent manner, but this effect was not affected by NOS inhibition. In contrast, isoproterenol reduced thrombin-induced platelet adhesion to endothelial cells, and this effect was blocked by NOS inhibition. The effect of isoproterenol on NOS activity and adhesion was confirmed to be mediated exclusively by beta(2)ARs. The study found that beta(2)ARs activate NOS through a cAMP-dependent pathway. The results suggest that beta(2)ARs contribute to platelet adhesion inhibition via NO production but not to aggregation inhibition.
Conclusions:
The authors concluded that beta(2)-adrenoceptors (beta(2)ARs) activate nitric oxide synthase (NOS) in human platelets through a cAMP-dependent mechanism. This activation is not associated with changes in intracellular calcium levels, indicating a calcium-independent pathway. The study found that beta(2)ARs contribute to the inhibition of platelet adhesion to endothelial cells, but not to the inhibition of aggregation. The anti-adhesive effect of isoproterenol was abolished by NOS inhibition, suggesting that NO production is essential for this effect. However, the anti-aggregatory effect of isoproterenol was not significantly affected by NOS inhibition. These findings suggest that beta(2)ARs modulate platelet function through NOS activation. The authors propose that the L-arginine/NO system mediates the effects of beta(2)ARs on adhesion but not on aggregation. The study provides evidence that beta(2)ARs may play a role in regulating platelet adhesion to endothelium via NO production. These results suggest that beta(2)ARs could be a target for modulating platelet behavior in specific contexts.
Frequently Asked Questions
The authors propose that beta(2)-adrenoceptors activate nitric oxide synthase (NOS) in platelets through a cAMP-dependent pathway. This activation increases NOS activity, leading to higher NO production.
cAMP appears to mediate the activation of NOS by beta(2)-adrenoceptors. The adenylyl cyclase inhibitor SQ22536 abolished NOS activation, indicating that cAMP is necessary for this process.
Intracellular calcium levels were measured to determine if NOS activation was calcium-dependent. The study found that NOS activation was not associated with changes in calcium, suggesting a calcium-independent mechanism.
Measuring adhesion to endothelial cells helped assess the anti-adhesive effects of isoproterenol. The study found that this effect was abolished by NOS inhibition, indicating that NO production mediates adhesion inhibition.
NOS activity was measured by tracking the conversion of L-[(3)H]-arginine to L-[(3)H]-citrulline in platelet samples. This method allowed the researchers to quantify NOS activity accurately.
The study suggests that beta(2)-adrenoceptors may modulate platelet adhesion to endothelium via NO production. However, they do not appear to significantly affect aggregation inhibition.